Aliquots Archives
Rheumatoid arthritis and heart disease: a common path
Aug. 25, 2022—An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered.
Inflammatory driver of obesity
Aug. 25, 2022—Blocking the EGF receptor signaling pathway in immune system macrophages represents a new target for improving insulin resistance in people with obesity.
Nanoparticles boost anti-cancer immunity
Aug. 16, 2022—An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.
Mitochondria and retinal degeneration
Aug. 15, 2022—Vanderbilt researchers have developed a new cellular model for exploring mitochondrial dysfunction in age-related macular degeneration, the leading cause of blindness in people over 65.
Genotype-specific blood counts
Aug. 11, 2022—Vanderbilt researchers report genotype-specific reference ranges to improve interpretation of laboratory blood results in African Americans with a common gene variant that lowers white blood cell counts.
Cell-free breast cancer “biopsy”
Aug. 11, 2022—The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
H. pylori and lung cancer
Aug. 1, 2022—Specific biomarkers for H. pylori — a bacterium that infects the stomach — were associated with increased risk of lung cancer, Vanderbilt researchers have discovered.
Video vital for telehealth visits
Jul. 28, 2022—Vanderbilt study of 18,130 telehealth visits at the beginning of the COVID-19 pandemic defines risk factors associated with telehealth access and suggests how health systems can improve access.
Specialty pharmacists help reduce MS relapse risk
Jul. 28, 2022—Just one-third of patients with relapsing multiple sclerosis remain on disease-modifying therapy, and specialty pharmacists are in a unique position to help coordinate therapy discontinuation or change and reduce the risk of relapse.
Probing the tumor microenvironment
Jul. 12, 2022—Vanderbilt researchers used single-cell sequencing, imaging, and computational approaches to characterize the colonic tumor microenvironment, providing important insights to the components that play roles in colorectal tumor pathogenesis.
A speedier treatment for depression?
Jul. 11, 2022—Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.
